Search clinical trials for: Node-negative hormone-receptor (HR) positive/ human epidermal growth factor receptor 2 (HER2)

Total 118375 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

HR-positive, HER2-negative Breast Neoplasms

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Advanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditions

United States
Washington University School of Medicine
Molecular Templates, Inc.

Withdrawn

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

HER2-positive Solid Tumor | HER-2 Positive Cancer
Pfizer

Completed

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Metastatic Breast Cancer

Israel
QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
Peking University Cancer Hospital & Institute

Recruiting

Research for the Molecular Imaging of the HER2 Targeting Tracer

HER2 Positive or Suspicious Positive Tumors

China
Palleos Healthcare GmbH
Roche Pharma AG; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP

Completed

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (TP-II)

Breast Neoplasms

Germany
Georgetown University
Pfizer

Active, not recruiting

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor Positive Breast Cancer

United States
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Advanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)

United States, Belgium, Canada, Italy, Spain, United Kingdom
Laura M. Spring, MD
Merck Sharp & Dohme LLC; Translational Breast Cancer Research Consortium; Breast...

Recruiting

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Triple Negative Breast Cancer | Hormone Receptor Positive (HR+), HER2-negative Breast Cancer | Biopsy-proven, Positive Lymph Node(s)

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer

Early-stage Breast Cancer | Breast Cancer Invasive | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

China
Pfizer

Completed

A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

Breast Neoplasms

Poland
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib With Everolimus + Exemestane In BC

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor (HR)-Positive Breast Cancer

United States
Henan Cancer Hospital

Recruiting

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Breast Cancer

China
Medical College of Wisconsin

Not yet recruiting

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Breast Cancer

United States
Pfizer

Completed

Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan

Breast Cancer

Japan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

HR Positive/HER2 Low Expression Metastatic Breast Cancer

China
QuantumLeap Healthcare Collaborative
Byondis B.V.

Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Ovarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditions

United States
G1 Therapeutics, Inc.

Active, not recruiting

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Breast Neoplasm | Carcinoma, Ductal, Breast

United Kingdom, Bulgaria, Georgia, Moldova, Republic of
Bio-Thera Solutions

Unknown

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

HER2-Positive Solid Tumors

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy (HERCREEM)

HER2 Positive Malignancies

United States
University of Milano Bicocca

Active, not recruiting

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7)

Advanced Breast Cancer

Italy
Hoffmann-La Roche

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC)

Breast Neoplasms

United States, Israel, Korea, Republic of
Pfizer

Active, not recruiting

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Metastatic Breast Cancer

Korea, Republic of
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

HR-positive, HER2-negative Advanced Breast Cancer

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Mexico, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa
Novartis Pharmaceuticals

Withdrawn

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

HR Positive HER2 Negative Advanced Breast Cancer

China
Chinese PLA General Hospital
Fudan University

Recruiting

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

HER2 Positive Advanced Solid Tumors

China
Mridula George, MD

Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Breast Cancer

United States
Orum Therapeutics USA, Inc.

Recruiting

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

United States
Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the Breast

United States
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
The First Affiliated Hospital with Nanjing Medical...
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Advanced Breast Cancer

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors (CART-HER-2)

Advanced HER-2 Positive Solid Tumors | Chemotherapy Refactory | HER-2 Antibody Inhibitor Therapy Refactory

China
Novartis Healthcare A/S

Completed

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Breast Cancer

Denmark
Providence Health & Services

Active, not recruiting

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Breast Cancer

United States
Seagen Inc.

Completed

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Triple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast Neoplasms

United States
Peking University
RemeGen Co., Ltd.

Recruiting

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

HER2-Positive Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Wuhan YZY Biopharma Co., Ltd.

Not yet recruiting

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

HER2-Positive Solid Tumors
Peking Union Medical College Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Pyrotinib)

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor
Peking University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

HER2 Positive Solid Tumor

China
Pfizer

Active, not recruiting

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Breast Cancer

United States
iOMEDICO AG
Novartis Pharmaceuticals

Completed

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line (RIBBIT)

Breast Cancer | Hormone Receptor Positive Tumor | HER 2 Negative Breast Cancer

Germany
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

HR Positive/HER-2 Negative Breast Cancer

China
Henan Cancer Hospital

Recruiting

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

HR Positive HER2 Negative Advanced Breast Cancer

China

Search clinical trials for: Node-negative hormone-receptor (HR) positive/ human epidermal growth factor receptor 2 (HER2)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations